141 related articles for article (PubMed ID: 24378707)
21. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
23. New trends in peptide receptor radioligands.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Andreae F; Kurtaran A; Dudczak R
Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
[TBL] [Abstract][Full Text] [Related]
24. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
25. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
Cescato R; Waser B; Fani M; Reubi JC
J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
[TBL] [Abstract][Full Text] [Related]
27. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of DOTA-conjugated multimeric [Tyr3]octreotide peptides via a combination of Cu(I)-catalyzed "click" cycloaddition and thio acid/sulfonyl azide "sulfo-click" amidation and their in vivo evaluation.
Yim CB; Dijkgraaf I; Merkx R; Versluis C; Eek A; Mulder GE; Rijkers DT; Boerman OC; Liskamp RM
J Med Chem; 2010 May; 53(10):3944-53. PubMed ID: 20411957
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
32. A microplate binding assay for the somatostatin type-2 receptor (SSTR2).
Froidevaux S; Meier M; Häusler M; Mäcke H; Beglinger C; Eberle AN
J Recept Signal Transduct Res; 1999; 19(1-4):167-80. PubMed ID: 10071756
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.
Reubi JC; Waser B; Schaer JC; Laissue JA
Eur J Nucl Med; 2001 Jul; 28(7):836-46. PubMed ID: 11504080
[TBL] [Abstract][Full Text] [Related]
35. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
36. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
37. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
38. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
39. A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors.
Reubi JC; Schaer JC; Waser B; Hoeger C; Rivier J
Eur J Pharmacol; 1998 Mar; 345(1):103-10. PubMed ID: 9593601
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of a ligand targeting the somatostatin-2 receptor for drug delivery to neuroendocrine cancers.
Li G; Low PS
Bioorg Med Chem Lett; 2015 Apr; 25(8):1792-1798. PubMed ID: 25791453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
